{
  "name": "Latigo Biotherapeutics, Inc.",
  "legal_name": "Latigo Biotherapeutics, Inc.",
  "ticker": "LTGO",
  "tickers": [
    "LTGO"
  ],
  "cik": "0002056611",
  "page_url": "https://steadybase.io/company/latigo-biotherapeutics-inc/",
  "markdown_url": "https://steadybase.io/company/latigo-biotherapeutics-inc.md",
  "json_url": "https://steadybase.io/company/latigo-biotherapeutics-inc.json",
  "as_of": "2026-11-21",
  "last_filed": "2026-11-05",
  "industry": {
    "sic": "2834",
    "description": "Pharmaceutical Preparations"
  },
  "headquarters": {
    "city": "Thousand Oaks",
    "state": "CA",
    "country": "US"
  },
  "exchanges": [
    "Nasdaq"
  ],
  "fiscal_year_end": "December 31",
  "filer_category": "Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company",
  "state_of_incorporation": "DE",
  "website": "latigobio.com",
  "investor_relations_url": "https://investors.latigobio.com/",
  "linkedin_company_url": "https://www.linkedin.com/company/latigobio",
  "summary": {
    "text": "Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality of life.",
    "section": "Company website description",
    "period_end": "2026-11-07",
    "source_url": "https://latigobio.com/"
  },
  "key_facts": [
    {
      "key": "shares_outstanding",
      "label": "Shares outstanding",
      "value": 66299347,
      "unit": "shares",
      "period_end": "2026-11-02",
      "form": "10-Q",
      "filed": "2026-11-05",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000119312526448582/0001193125-26-448582-index.html",
      "text": "Shares outstanding: 66,299,347 as of Nov 2, 2026 (10-Q filed Nov 5, 2026)."
    }
  ],
  "metrics": {},
  "next_earnings": {
    "date": "2026-12-03",
    "confidence": "unconfirmed",
    "webcast_url": null
  },
  "people": [
    {
      "name": "Todd N. Smith",
      "title": "President and CEO",
      "role": "both",
      "linkedin_url": null,
      "form": "4",
      "filed": "2026-11-18",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000152367226000010/0001523672-26-000010-index.htm"
    },
    {
      "name": "Nima Farzan",
      "title": "President and CEO",
      "role": "both",
      "linkedin_url": "https://linkedin.com/in/nima-farzan-bb293",
      "form": "3",
      "filed": "2026-08-06",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000180829626000006/0001808296-26-000006-index.htm"
    },
    {
      "name": "Neha Krishnamohan",
      "title": "CFO and Chief Business Officer",
      "role": "officer",
      "linkedin_url": "https://linkedin.com/in/neha-krishnamohan",
      "form": "3",
      "filed": "2026-08-06",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000186617126000002/0001866171-26-000002-index.htm"
    },
    {
      "name": "Neil Singla",
      "title": "Chief Medical Officer",
      "role": "officer",
      "linkedin_url": "https://linkedin.com/in/neil-singla-md",
      "form": "3",
      "filed": "2026-08-06",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000214374126000002/0002143741-26-000002-index.htm"
    }
  ],
  "events_8k": [
    {
      "filed": "2026-11-05",
      "items": [
        {
          "item": "2.02",
          "label": "Results of operations and financial condition (earnings release)",
          "signal": "earnings"
        },
        {
          "item": "5.02",
          "label": "Departure or appointment of directors or officers; compensation",
          "signal": "leadership_change"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000119312526448537/ltgo-20261103.htm"
    },
    {
      "filed": "2026-09-03",
      "items": [
        {
          "item": "2.02",
          "label": "Results of operations and financial condition (earnings release)",
          "signal": "earnings"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000119312526381912/ltgo-20260903.htm"
    },
    {
      "filed": "2026-08-10",
      "items": [
        {
          "item": "5.03",
          "label": "Amendments to articles or bylaws; change in fiscal year",
          "signal": "governance"
        },
        {
          "item": "8.01",
          "label": "Other events",
          "signal": "other"
        },
        {
          "item": "9.01",
          "label": "Financial statements and exhibits",
          "signal": "exhibits"
        }
      ],
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000119312526342321/d170764d8k.htm"
    }
  ],
  "insider_trades": [
    {
      "owner": "James B. Tananbaum",
      "role": "Director",
      "action": "bought",
      "code": "P",
      "shares": 140000,
      "value_usd": 2520000,
      "date": "2026-08-10",
      "filed": "2026-08-10",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000158175426000006/0001581754-26-000006-index.htm"
    }
  ],
  "quotes": [
    {
      "text": "With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program",
      "speaker": "Todd N. Smith",
      "title": "president and chief executive officer, Latigo",
      "form": "8-K",
      "filed": "2026-11-05",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000119312526448537/ltgo-ex99_1.htm"
    }
  ],
  "latest_filings": [
    {
      "form": "8-K",
      "filed": "2026-09-03",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000119312526381912/ltgo-20260903.htm"
    },
    {
      "form": "10-Q",
      "filed": "2026-09-03",
      "source_url": "https://www.sec.gov/Archives/edgar/data/2056611/000119312526381969/ltgo-20260630.htm"
    }
  ],
  "source": "SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from."
}